5月28日，派格生物医药-B盘中上涨10.77%，报9.71港元/股，成交额365.18万港元。
消息面上，该股昨日恰逢上市满一周年，IPO前股东所持股份禁售期全面到期，大量低成本筹码集中解禁，盘中一度重挫逾15%，股价最低触及8.78港元。经历单日急跌后，今日出现超跌反弹，但当前股价仍显著低于上周14元以上水平，短期走势或仍受解禁后筹码消化节奏影响。
派格生物医药是一家深耕慢病代谢领域的生物科技公司，核心产品为接近商业化阶段的长效GLP-1受体激动剂PB-119，主要用于治疗2型糖尿病及肥胖症等代谢疾病。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.